Deltarasin
Cat.No:ID2650 Solarbio
CAS:1440898-61-2
Molecular Formula:C40H37N5O
Molecular Weight:603.75
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to yellow Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Others >
DeltarasinCAS:1440898-61-2
Molecular Formula:C40H37N5O
Molecular Weight:603.75
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to yellow Solid
Qty:
Size:
CAS | 1440898-61-2 |
Name | Deltarasin |
Molecular Formula | C40H37N5O |
Molecular Weight | 603.75 |
Solubility | Soluble in DMSO ≥5mg/mL |
Purity | ≥98% |
Appearance | White to yellow Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
SMILES | C1(C2=CC=C(OC[C@@H](N3C4=CC=CC=C4N=C3C5=CC=CC=C5)C6CCNCC6)C=C2)=NC7=CC=CC=C7N1CC8=CC=CC=C8 |
Target Point | KRAS-PDEδ |
Passage | Others |
Background | Deltarasin is a small molecule inhibitor that inhibits the KRAS-PDEδ interaction. |
Biological Activity | Deltarasin 是一种 KRAS-PDEδ 相互作用的抑制剂,能够与 PDEδ 结合,Kd 值为 38 nM。[1-2] |
Data Literature Source | [1]. Zimmermann G,et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013 May 30;497(7451):638-42. [2]. Agalioti T,et al. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017 May 16;8:15205. doi: 10.1038/ncomms15205 |
Unit | Bottle |
Specification | 2mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.